Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BIO-TECHNE Corp reported revenue of $1.22B, up 5.2% year over year. Operating margin was 8.4% and net margin 6.0%, on a free-cash-flow margin of 21.0% with capital expenditure at 2.5% of revenue. Every figure is computed directly from TECH's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1.22B | 8.4% | 6.0% |
| FY2024 | $1.16B | 17.8% | 14.5% |
| FY2023 | $1.14B | 26.3% | 25.1% |
| FY2022 | $1.11B | 26.8% | 24.6% |
| FY2021 | $931M | 25.5% | 15.1% |
How does TECH compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.